Transhiatal esophagectomy for benign and malignant conditions

Am J Surg. 2002 Aug;184(2):136-42. doi: 10.1016/s0002-9610(02)00906-6.

Abstract

Background: Experience with transhiatal esophagectomy (THE) for both benign and malignant diseases of the esophagus as practiced over an 18-year period is presented.

Methods: Between 1982 and 2000, 411 consecutive patients underwent THE for both benign (n = 44) and malignant (n = 367) diseases of esophagus. Surviving patients were followed up for a mean of 30.4 months.

Results: The overall operative mortality was 11% which had reduced to 6% for the last 111 patients. Operative mortality in the benign group was less than 5%. Respiratory complications were the most frequent cause of morbidity and mortality. Nonfatal anastomotic leaks occurred in 14%. The overall actuarial survival rates at 2, 5, and 10 years for carcinoma patients were 54%, 38%, and 18% respectively. The 2- and 5-year actuarial survival rates for postcricoid cancers were 83% and 64%, respectively.

Conclusions: Transhiatal esophagectomy is safe and effective, and its results including long-term outcome are comparable with most published series.

MeSH terms

  • Adolescent
  • Adult
  • Biopsy, Needle
  • Carcinoma, Squamous Cell / mortality
  • Carcinoma, Squamous Cell / pathology*
  • Carcinoma, Squamous Cell / surgery*
  • Child
  • Cohort Studies
  • Disease-Free Survival
  • Esophageal Diseases / mortality
  • Esophageal Diseases / pathology
  • Esophageal Diseases / surgery
  • Esophageal Neoplasms / mortality
  • Esophageal Neoplasms / pathology*
  • Esophageal Neoplasms / surgery*
  • Esophagectomy / methods*
  • Esophagoscopy
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Probability
  • Retrospective Studies
  • Statistics, Nonparametric
  • Survival Analysis
  • Time Factors
  • Treatment Outcome